Drugs / Autologous Plasmablasts (B cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05682144 | Apr 2023 → Jun 2029 expected | Hurler-Scheie syndrome, Scheie syndrome | Immusoft of CA, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Plasmablasts (B cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05682144 ↗ |
| Modality | Cell therapy | “Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.” NCT05682144 ↗ |